ClinicalTrials.gg
WithdrawnNCT02292459Updated Jul 16, 2015

Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)

A Phase 3 interventional study of Polyethylene Glycol 3350 Powder for Solution (PEG 3350) and Polyethylene Glycol 4000 Powder for Solution (PEG 4000) in Constipation, sponsored by Bayer. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-16.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing polyethylene glycol 3350 in Constipation — 3 open to participants now, 4 under way, none of them phase 3. polyethylene glycol 3350 · Constipation.

Enrollment
25th of 27
0 · median 100
Started
2015
the only one that year
Phase 3
3 of 27
none open now
Registered
17th of 27
by date
Lead sponsor
3 of 27
Bayer

Among the 27 studies testing polyethylene glycol 3350 in Constipation, this one is the 25th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 3, and was the 17th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 27 studies testing polyethylene glycol 3350 in Constipation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About polyethylene glycol 3350

polyethylene glycol 3350: first FDA approval 1984 (GOLYTELY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing polyethylene glycol 3350 in Constipation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the complete resolution of constipation in participants taking PEG 3350 compared to those taking PEG 4000, based on analysis of the number of bowel movements from self-reported bowel movement (BM) data. The complete resolution of constipation is defined as the elimination of straining or of hard/lumpy stools.

03

Conditions studied

  • Constipation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • meets diagnostic criteria for functional constipation. This includes loose stools that are rarely present without the use of laxatives and 2 or more of the following: straining during at least 25% of defecations; lumpy or hard stools in at least 25% of defecations; sensation of incomplete evacuation for at least 25% of defecations; sensation of anorectal obstruction/blockage for at least 25% of defecations; manual maneuvers to facilitate at least 25% of defecations [e.g., digital evacuation, support of the pelvic floor]; and fewer than 3 defecations per week. Criteria for functional constipation must be fulfilled for last 3 months, with symptom onset at least 6 months prior to diagnosis.
  • willing to use study drug for up to 7 days as directed, and must agree to record bowel movements (frequency, consistency, etc.) accurately and consistently in a daily diary, and make 3 clinic visits.
  • except for constipation, must be otherwise in good health, as determined by physical exam and medical history.
  • agrees not to use any other products (drug, herbal, dietary supplements including fiber, etc.) to treat their constipation during the course of the study.
  • agrees not to use any medication known to cause constipation during the course of the study.
  • agree to maintain a similar diet from the week prior to randomization through the end of the study.
  • females must be either surgically sterile, 2 years , or attest that they are using an acceptable method of (including hormonal birth control, intrauterine device [IUD], double barrier methods, or vasectomized partner).
  • females of must have urine pregnancy test (human chorionic gonadotropin [HCG]) that is negative at Baseline.
  • must be able to read the diaries in Russian.

Exclusion Criteria: - currently under a doctor's care and treatment for constipation.

  • have current constipation episode for more than one week prior to randomization.
  • history of chronic constipation due to any underlying cause (inflammatory bowel disease, etc.).
  • history of more than 3 months of constipation in the past year.
  • have severe abdominal pain as the predominant constipation symptom.
  • had with bowel movement in 48 hours prior to randomization.
  • have celiac disease or known gluten sensitivity.
  • history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy.
  • have known renal or hepatic insufficiency.
  • have gastrointestinal bleeding or acute infection.
  • history of alcohol or drug abuse.
  • history of psychiatric disorders.
  • history of significant ongoing medical problems, including kidney disease, or are scheduled for surgical procedures.
  • currently taking or have taken within 7 days of randomization a concomitant medication that causes constipation, including opiates, antidepressants, selective serotonin reuptake inhibitors (SSRIs), antimotility agents, and anticholinergics, etc.
  • plan to use laxatives during the treatment period other than the study medication.
  • have participated in an clinical, surgical, drug or device study within the past 30 days. (Concurrent skin patch testing of cosmetic or suncare products is allowed.)
  • pregnant or lactating.
  • allergic to polyethylene glycol or maltodextrin.
  • employed or have immediate family members employed by a company that manufactures laxative products.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    PEG 3350

    Participants will receive a 17 g oral dose of 1 sachet of PEG 3350 mixed in 120 to 240 mL of water, once a day, for 7 days.

    Drug: Polyethylene Glycol 3350 Powder for Solution (PEG 3350)

  • Active comparator
    PEG 4000

    Participants will receive a 10 to 20 g oral dose of 1 to 2 sachets of PEG 4000 mixed in 120 to 140 mL of water, once a day, for 7 days.

    Drug: Polyethylene Glycol 4000 Powder for Solution (PEG 4000)

06

What researchers measure

Primary outcomes

  1. Number of bowel movements per week

    Time frame: Up to 7 days after start of treatment

Secondary outcomes

  1. Time to first bowel movement

    Time frame: Up to 7 days after start of treatment

  2. Number of participants who experience changes in straining and hard or lumpy stools

    Time frame: Up to 7 days after start of treatment

  3. Number of participants who experience changes in stool consistency

    Time frame: Up to 7 days after start of treatment

  4. Number of participants who experience changes in the sensation of stool evacuation

    Time frame: Up to 7 days after start of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2014
First posted
Nov 17, 2014
Start
Dec 2015
Primary completionEst.
Dec 2015
CompletionEst.
Dec 2015
Last update
Jul 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02292459
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 17, 2014
Start date
Dec 2015
Primary completion
Dec 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Jul 16, 2015

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Polyethylene glycol 3350

Start the discussion